source
- Aspen Neuroscience raises $140M IPO to advance Parkinson’s cell therapyAspen Neuroscience, a San Diego biotechnology company, completed an initial public offering, selling roughly 9.4 million shares at $15 each and raising about $140.6 million. The capital will be di…
- Genmab shares jump as petosemtamab plus Keytruda halves death risk in head-neck cancer trialGenmab reported that a late-stage study of its experimental antibody petosemtamab combined with Keytruda cut the risk of death by about 50 percent compared with Keytruda alone in patients with PD‑L…